3,6-Disubstituted azabicyclo derivatives as muscarinic...

Details 3,6-Disubstituted azabicyclo derivatives as muscarinic... 3,6-Disubstituted azabicyclo derivatives as muscarinic...

2007-06-19

2007-06-19

Seaman, D. Margaret (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S214010, C540S584000, C546S112000

Reexamination Certificate

active

10537851

ABSTRACT:
This invention relates to derivatives of 3,6-disubstituted azabicyclo compounds. The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.

REFERENCES:
patent: 3176019 (1965-03-01), Campbell et al.
patent: 5281601 (1994-01-01), Cross et al.
patent: 5397800 (1995-03-01), Alker et al.
patent: 5703091 (1997-12-01), Steiner et al.
patent: 5914338 (1999-06-01), Jeppesen et al.
patent: 5948792 (1999-09-01), Tsuchiya et al.
patent: 6130232 (2000-10-01), Mase et al.
patent: 6174900 (2001-01-01), Okada et al.
patent: 0 132 130 (1985-01-01), None
patent: 0 325 571 (1989-07-01), None
patent: 0 388 054 (1990-09-01), None
patent: 0 801 067 (1997-10-01), None
patent: 0 823 423 (1998-02-01), None
patent: 0 863 141 (1998-09-01), None
patent: 0 930 298 (1999-07-01), None
patent: 940540 (1963-10-01), None
patent: 92921/1994 (1994-04-01), None
patent: 135958/1994 (1994-05-01), None
patent: WO 91/09013 (1991-06-01), None
patent: WO 93/16018 (1993-08-01), None
patent: WO 93/16048 (1993-08-01), None
patent: WO 96/33973 (1996-10-01), None
patent: 97/36871 (1997-09-01), None
patent: WO 97/45414 (1997-12-01), None
patent: WO 98/05641 (1998-02-01), None
patent: WO 98/29402 (1998-07-01), None
patent: WO 04/004629 (2004-01-01), None
patent: WO 04/005252 (2004-01-01), None
Messaoik et al., International Journal of Pharmaceutics, “Comparative study and optimisation of the administration mode of three proton pump inhibitors by nasogastric tube”, 2005, vol. 299, pp. 65-72.
Chang-Young Lim et al., Journal of Clinical Microbiology, “Detection of Helicobacter pylori in Gastric Mucosa of patients with Gastroduodenal Diseases by PRC-Restriction Analysis using the RNA Polymerase Gene (rpoB)”, 2003, vol. 41, pp. 3387-3391.
Kubo et al., “Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor”,Nature, 323(2):411-416 (1986).
Bonner et al., “Identification of a Family of Muscarinic Acetylcholine Receptor Genes”,Science, 237:527-531 (1987).
Eglen et al., “Muscarinic receptor ligands and their theraputic potential”,Current Opinion in Chemical Biology, 3:426-432 (1999).
Eglen et al., “Theraputic opportunities from muscarinic receptor research”,Trends in Pharmacological Sciences, 22(8):409-414 (2001).
Felder et al., “Theraputic Opportunities for Muscarinic Receptors in the Central Nervous System”,Journal of Medicinal Chemistry, 43(23):4333-4353 (2000).
Broadley and Kelly, “Muscarinic Receptor Agonists and Antagonists”,Molecules, 6:142-193 (2001).
Birdsall et al., “Muscarinic receptors: it's a knockout”,Trends in Pharmacological Sciences, 22(5):215-219 (2001).
de Groat and Yoshimura, “Pharmacology of the Lower Urinary Tract”,Annual Review of Pharmacology and Toxicology, 41:691-721 (2001).
Steers, “The future direction of neuro-urology drug research”,Current Opinion in CPNS Investigational Drugs, 2(3):268-282 (2000).
Chapple, “Muscarinic receptor antagonists in the treatment of overactive bladder”,Urology, 55(Suppl. 5A):33-46 (2000).
Steers, Barrot, Wein, “Voiding dysfunction: diagnosis classification and management”, In:Adult and Pediatric Urology, ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996).
Sagara et al., “Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M3 Antagonist Discriminating against the Other Receptor Subtypes”,Journal of Medicinal Chemistry, 45:984-987 (2002).
Vogel's textbook, “Practical Organic Chemistry” 1046-1047 (5th Ed.).
Braish et al., “Construction of the (1α,5α,6α)-6-Amino-3-azabicyclo[3.1.0]hexane Ring System”,Synlett, 1100-1102 (1996).
Vogel's textbook, “Practical Organic Chemistry” 1048-1051 (5th Ed.).
Shacklett and Smith, “The Preparation of Substituted Benzilic Acids”,Journal of the American Chemical Society, 75:2654-2657 (1953).
Gotteland et al., “(Aryloxy)methylsilane Derivatives as New Cholesterol Biosynthesis Inhibitors: Synthesis and Hypocholesterolemic Activity of a New Class of Squalene Epoxidase Inhibitors”,Journal of Medicinal Chemistry, 38:3207-3216 (1995).
Weinstock et al., “A General, One-Step Synthesis of α-keto Esters”,Synthetic Communications, 11(12):943-946 (1981).
Cornforth et al., “General Synthetic Routes to β-Hydroxy-acids from t-Butyl Esters and the Reformatskii Reaction”,Journal of the Chemical Society C, 20:2799-2805 (1969).
Grover et al., “Chiral Mandelic Acid Template Provides a Highly Practical Solution for (S)-Oxybutynin Synthesis”,Journal of Organic Chemistry, 65:6283-6287 (2000).
Moriya et al., “Affintity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAchR) Subtypes and mAChRs in Rat Heart and Submandibular Gland”,Life Sciences, 64(25):2351-2358 (1999).
Cheng and Prusoff, “Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction”,Biochemical Pharmacology, 22:3099-3108 (1973).

Affiliated with

Also associated with

Rating

3,6-Disubstituted azabicyclo derivatives as muscarinic... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3,6-Disubstituted azabicyclo derivatives as muscarinic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3,6-Disubstituted azabicyclo derivatives as muscarinic... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3846495